Phaseline

Targets › GNE

GNE (Bifunctional UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase): drug programs, companies and trials

1 program from 1 company in 2 trials: 2 Phase 2; Neurology, Genitourinary.

Bifunctional enzyme that possesses both UDP-N-acetylglucosamine 2-epimerase and N-acetylmannosamine kinase activities, and serves as the initiator of the biosynthetic pathway leading to the production of N-acetylneuraminic acid (NeuAc), a critical precursor in the synthesis of sialic acids. By catalyzing this pivotal and rate-limiting step in sialic acid biosynthesis, this enzyme assumes a pivotal role in governing…. (UniProt, Q9Y223)

Open in Phaseline: the race on GNE, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Leadiant BiosciencesManNAc (N-acetyl-D-mannosamine monohydrate)
Precursor for N-acetylneuraminic acid (Neu5Ac) biosynthesis; restores glycan sialylation i
GNEPhase 2GNE Myopathy; Focal Segmental Glomerulosclerosis–

Conditions

GNE Myopathy (1) Focal Segmental Glomerulosclerosis (1)

Modalities

small molecule (1)

Companies

Leadiant Biosciences (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.